List of Excipients in Branded Drug NYSTATIN CREAM

Generic Drugs Containing NYSTATIN CREAM

Company	Ingredient	NDC	Excipient
Crown Laboratories	nystatin cream	0316-0221	CETYL PALMITATE
Crown Laboratories	nystatin cream	0316-0221	MINERAL OIL
Crown Laboratories	nystatin cream	0316-0221	POTASSIUM SORBATE
Crown Laboratories	nystatin cream	0316-0221	PROPYLENE GLYCOL
Crown Laboratories	nystatin cream	0316-0221	SORBIC ACID
Crown Laboratories	nystatin cream	0316-0221	SORBITOL
Crown Laboratories	nystatin cream	0316-0221	WATER

What are the Most Frequently-Used Excipients in NYSTATIN CREAM?

# Of NDCs	Excipient
2	CETYL PALMITATE
2	MINERAL OIL
2	POTASSIUM SORBATE
2	PROPYLENE GLYCOL
2	SORBIC ACID
2	SORBITOL
2	WATER

Nystatin Cream Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: July 31, 2026

Nystatin cream is a mature topical antifungal product with limited active-ingredient exclusivity and substantial room for differentiation through formulation design, packaging, tolerability, microbiological performance, and channel strategy. The standard product contains nystatin at 100,000 units per gram, generally in an oil-in-water cream base. Commercial opportunity is concentrated in preservative selection, low-irritancy formulations, pediatric and sensitive-skin positioning, improved dispensing systems, and combination products rather than in new chemical-entity patents.

What is the FDA regulatory status of nystatin cream?

Nystatin cream is an FDA-approved topical prescription antifungal for cutaneous and mucocutaneous infections caused by susceptible Candida species. The usual labeled strength is 100,000 units/g. Nystatin is a polyene antifungal that binds ergosterol in fungal cell membranes.

Attribute	Nystatin cream
Active ingredient	Nystatin
Typical strength	100,000 units/g
Dosage form	Topical cream
FDA pathway	NDA and ANDA products
Primary indication	Cutaneous or mucocutaneous candidiasis
Typical application	Two or more times daily, depending on product labeling
Prescription status	Generally prescription-only in the United States
Therapeutic class	Topical antifungal
Main competitors	Clotrimazole, miconazole, ketoconazole, terbinafine and combination corticosteroid products

FDA-approved labeling generally directs application to affected areas after cleansing and drying. Product labels warn against use in the eyes and typically distinguish topical skin products from vaginal or oral nystatin dosage forms.[1]

How does nystatin cream compare with competing topical antifungals?

Nystatin has a narrower commercial positioning than azole antifungals because it is primarily used for Candida infections and has limited activity against dermatophytes. Clotrimazole and miconazole have broader use in common athlete's foot, ringworm and jock itch indications. Terbinafine is often preferred for dermatophyte infections because of shorter treatment courses.

Nystatin retains value in Candida-focused treatment, including intertriginous candidiasis, diaper-area candidiasis and infections where clinicians prefer a non-azole antifungal. Formulation performance and tolerability can be more important than broad-spectrum claims in these segments.

Product category	Main commercial advantage	Main limitation
Nystatin cream	Established Candida efficacy and low-cost manufacturing	Narrower spectrum and limited differentiation
Clotrimazole cream	Broad consumer recognition and wide antifungal positioning	Azole-class resistance and irritation concerns in some users
Miconazole cream	Broad OTC distribution and multiple dosage forms	Crowded market
Terbinafine cream	Short-course treatment for dermatophytes	Less directly aligned with Candida-focused use
Nystatin-steroid combination	Anti-inflammatory positioning	Greater safety and regulatory complexity

What excipients are used in nystatin cream?

Nystatin cream products commonly use a semi-solid emulsion containing an oil phase, aqueous phase, emulsifiers, fatty alcohols, humectants, preservatives and viscosity modifiers. The exact excipient profile differs by manufacturer and approved product.

Common excipient categories include:

Excipient function	Examples used in topical creams	Commercial purpose
Emollient and occlusive	Mineral oil, petrolatum, white petrolatum	Reduces water loss and improves skin feel
Structuring agent	Cetyl alcohol, stearyl alcohol, cetostearyl alcohol	Builds viscosity and cream body
Emulsifier	Polysorbate 60, sorbitan monostearate, sodium lauryl sulfate	Stabilizes oil-water systems
Humectant or solvent	Propylene glycol, glycerin	Supports hydration and ingredient dispersion
Preservative	Methylparaben, propylparaben or other approved systems	Controls microbial growth in multidose products
Chelating agent	Edetate disodium	Supports preservative performance and stability
Vehicle	Purified water	Continuous aqueous phase
pH modifier	Product-specific acids, bases or buffers	Controls stability and skin compatibility

The inactive ingredients must be taken from the labeling for the specific product. Formulations sold under the same active ingredient and strength can differ materially in preservative system, surfactant level, occlusivity, viscosity and sensory profile.[1,2]

Which excipients create the greatest formulation risk?

Preservatives, surfactants and glycols are the main tolerability and development-risk categories.

Propylene glycol can improve solubilization and skin hydration but may cause irritation in compromised skin or pediatric use. Sodium lauryl sulfate can improve emulsification but has a higher irritation profile than milder nonionic emulsifiers. Parabens are effective and familiar to formulators, but some customers and institutional purchasers prefer paraben-free products.

Fatty alcohols such as cetyl alcohol and stearyl alcohol are generally used as structural excipients rather than volatile alcohols. They improve viscosity and spreadability but can produce a waxy feel if used at excessive concentrations.

Petrolatum and mineral oil improve barrier performance and can support use in intertriginous or diaper-area applications. Excessive occlusion, however, can reduce consumer acceptability in warm climates and may make the product difficult to wash from clothing.

How should an excipient strategy be designed for nystatin cream?

A commercially viable formulation strategy should start with the target segment rather than with a generic excipient substitution.

Sensitive-skin and pediatric formulation

For diaper-area and pediatric use, the preferred profile is typically:

• Low fragrance or fragrance-free composition
• Low-irritancy emulsifier system
• Controlled preservative burden
• Minimal unnecessary colorants
• Moderate occlusivity
• Easy spreading without excessive tack
• Packaging that limits contamination

A paraben-free formulation may improve marketability, but preservative replacement must be supported by antimicrobial effectiveness testing and product-specific stability data. Replacing parabens with phenoxyethanol, organic acids or multifunctional humectants can change pH requirements, odor, skin feel and preservative efficacy.

Barrier-support formulation

A more occlusive cream can position nystatin for candidal intertrigo and diaper-associated candidiasis. Petrolatum, mineral oil and selected fatty alcohols can improve barrier support. This approach creates a clearer product distinction from thin, fast-absorbing antifungal creams.

The formulation must avoid implying that the product treats noninfectious diaper dermatitis unless the label supports that use. Promotional claims should remain consistent with the approved indication and labeling.

Cosmetic-sensory formulation

A lighter cream can target adult users who reject greasy ointments. Lower oil loading, smaller droplet size and optimized emulsifier selection can improve spreadability and residue. The tradeoff is reduced occlusion and potentially greater water loss from the skin.

A differentiated sensory profile may support pharmacy-brand, telehealth and private-label opportunities even when the active ingredient and strength are identical to incumbent products.

Preservative-free or unit-dose formulation

A preservative-free product could be commercially attractive for highly sensitive skin, but it would require a packaging and microbiological strategy that compensates for the absence of a conventional preservative system. Possible approaches include:

• Single-use sachets
• Small-volume unit-dose tubes
• Airless pumps
• Controlled-dose dispensing systems
• Reduced-contact packaging

The commercial value depends on whether higher packaging cost is offset by premium pricing, reduced contamination risk or institutional demand.

What formulations are protected by patents?

Nystatin itself is an old active ingredient, and basic nystatin cream formulations are generally exposed to extensive generic competition. The principal barriers are regulatory approval, manufacturing know-how, product quality and market access rather than active-ingredient patent exclusivity.

Are there formulation patents for nystatin cream?

Formulation patents may exist for specific combinations involving:

• Novel emulsions
• Enhanced skin penetration
• Sustained release
• Combination antifungal and corticosteroid products
• Liposomal or nanoparticle delivery
• Mucoadhesive systems
• Improved stability or reduced irritation
• Alternative packaging and dispensing systems

A patent directed to a particular excipient ratio, particle-size distribution, delivery system or manufacturing process may not cover a conventional nystatin cream. Freedom-to-operate analysis therefore must distinguish ordinary cream products from specialized delivery platforms.

The commercial relevance of a formulation patent depends on claim breadth, enablement, prosecution history, continuation activity, terminal disclaimers, litigation history and the existence of design-around formulations. Because nystatin has no meaningful new-molecule exclusivity period, any defensible protection must usually come from a narrowly defined formulation, delivery system, process or use.

What is the Orange Book status of nystatin cream?

Nystatin cream products may appear in FDA-approved product databases through NDA or ANDA records, but Orange Book treatment depends on the specific approved product and dosage-form listing. The presence of an approved generic does not mean every topical cream has identical inactive ingredients or equivalent commercial characteristics.

For an abbreviated application, the applicant generally must demonstrate pharmaceutical equivalence and bioequivalence under the applicable FDA requirements. Topical products may require product-specific performance or comparative studies depending on the dosage form and regulatory pathway.[3]

The relevant diligence points are:

1. Identify the reference-listed drug for the exact cream strength and dosage form.
2. Confirm whether the proposed product qualifies for an ANDA pathway.
3. Review listed patents and regulatory exclusivities for the reference product.
4. Compare inactive ingredients against FDA inactive-ingredient limits and prior approved use.
5. Assess whether a change in excipients could affect bioequivalence or local performance.

When does nystatin cream lose exclusivity?

Nystatin cream is generally beyond the practical period of new-chemical-entity exclusivity. Generic entry has occurred, and multiple manufacturers compete through approved creams, ointments, powders and other nystatin dosage forms.

The relevant commercial question is not when nystatin loses molecule exclusivity. It is whether a particular branded or authorized-generic product has remaining protection from:

• Formulation patents
• Method-of-use patents
• Packaging patents
• Manufacturing-process patents
• Regulatory exclusivity
• Contractual market arrangements
• Channel-specific private-label agreements

A conventional nystatin cream with no active patent or regulatory exclusivity is exposed to generic launch once an applicant receives FDA approval and satisfies applicable certification requirements.

What Paragraph IV challenges and litigation affect nystatin cream?

Paragraph IV risk is product-specific. An ANDA applicant may challenge listed patents by asserting that the patent is invalid, unenforceable or not infringed. For a mature nystatin cream product, the most likely targets would be formulation, process or use claims rather than the nystatin molecule itself.

Potential litigation issues include:

• Whether the generic uses the same or a noninfringing excipient system
• Whether a cream composition claim covers a broad concentration range
• Whether a method-of-use claim is directed to an FDA-approved indication
• Whether the patent is properly listed for the relevant dosage form
• Whether the patent has expired or is subject to a terminal disclaimer
• Whether the applicant has made a section viii statement for a carve-out indication

A conventional product with no active formulation patent presents low patent-litigation exposure. A proprietary delivery platform can produce higher litigation risk but may support higher pricing and stronger switching barriers.

How strong is the patent estate for nystatin cream?

The patent estate for ordinary nystatin cream is weak from a composition-of-matter perspective and typically moderate to weak from a conventional formulation perspective. Patent strength improves when claims cover a clinically meaningful performance attribute that competitors cannot easily reproduce.

Protection type	Likely strength for standard nystatin cream	Commercial assessment
Nystatin molecule patent	Very low	Mature active ingredient
Basic cream vehicle	Low	Easy design-around risk
Specific excipient ratio	Low to moderate	Depends on claim breadth and evidence
Preservative-free delivery	Moderate	Packaging and microbiology may create differentiation
Unit-dose or airless package	Moderate	Useful for contamination and premium positioning
Novel delivery system	Moderate to high	Higher development and litigation cost
Method-of-use claim	Variable	Depends on indication and enforceability
Manufacturing process	Moderate	Stronger if process is difficult to replicate

Clinical or stability data can improve the value of formulation claims. A patent that merely lists familiar excipients without showing an unexpected technical effect is more vulnerable to obviousness challenges.

Which companies are challenging nystatin cream products?

The nystatin cream market is characterized by generic manufacturers, contract manufacturers, pharmacy suppliers and branded topical companies. Competition is usually based on price, supply reliability, formulation tolerability, tube size, packaging and distribution rather than on major patent challenges.

Generic competition can come from manufacturers with approved ANDA products and from companies marketing authorized or private-label products. The competitive field may change through product discontinuations, supply interruptions, acquisition of abbreviated applications and pharmacy-benefit formulary decisions.

Publicly available data do not generally provide a standalone revenue figure for nystatin cream by manufacturer. Companies often report topical antifungal sales within broader prescription, generic or consumer-health categories.

What commercial opportunities exist for nystatin cream?

Premium sensitive-skin product

A fragrance-free, low-irritancy cream with a controlled preservative system could target pediatric dermatology, recurrent intertrigo and patients with compromised skin barriers. The opportunity is strongest where prescribers value tolerability and patients reject greasy or irritating products.

Dermatology and telehealth channels

Telehealth providers and digital pharmacies can use standardized nystatin cream products in treatment protocols for candidal intertrigo and other Candida-associated skin conditions. Packaging, adherence instructions and refill convenience can differentiate the product without changing the active ingredient.

Institutional and long-term-care supply

Long-term-care facilities, hospitals and outpatient clinics may value:

• Reliable unit-dose packaging
• Tamper-evident tubes
• Clear lot and expiration labeling
• Consistent tube sizes
• Low-cost contract supply
• Reduced contamination during repeated application

Combination-product development

Nystatin can be combined with corticosteroids or antibacterial agents in products aimed at mixed clinical presentations. This strategy has higher regulatory and safety risk. Corticosteroid combinations require careful control of potency, duration of use, pediatric warnings and labeling claims. A combination product may also face greater clinical, pharmacovigilance and state-of-practice scrutiny than plain nystatin cream.

International and emerging-market products

Geographic opportunities include markets where topical Candida treatment remains underserved or where local manufacturing can reduce cost. Regulatory requirements, permitted preservatives, labeling language, GMP compliance and local reference products must be assessed separately by jurisdiction.

A product approved in the United States does not automatically establish approval or patent freedom in Europe, Canada, Latin America or Asia. Geographic freedom to operate requires country-specific patent and regulatory review.

What manufacturing and IP barriers affect nystatin cream?

The main manufacturing barriers are process consistency and microbiological control. Critical parameters include:

• Nystatin potency and assay uniformity
• Particle dispersion
• Emulsion droplet-size distribution
• Viscosity and yield stress
• Homogeneity during filling
• Preservative effectiveness
• Container compatibility
• Stability under temperature excursions
• Tube or pump fill-weight accuracy

Nystatin is sensitive to formulation and processing conditions. Excessive shear, unsuitable pH, prolonged heat exposure or poor dispersion can reduce potency or create content-uniformity problems. The manufacturing process must preserve antifungal activity while producing a stable, cosmetically acceptable cream.

Packaging is part of the quality strategy. Aluminum tubes can provide strong barrier protection but may require internal coatings. Laminated tubes and plastic tubes may improve consumer convenience but require extractables, leachables and compatibility assessment.

What generic launch scenarios exist for nystatin cream?

Low-cost conventional generic

The most likely entry model is a standard 100,000 units/g cream using familiar excipients and a conventional tube. Competition is primarily price-driven, with limited patent risk.

Differentiated excipient generic

A manufacturer can use a paraben-free, fragrance-free or lower-irritancy system to obtain pharmacy and prescriber differentiation. The product may command a modest premium if supported by consistent supply and acceptable sensory performance.

Premium packaging product

An airless pump, unit-dose pack or contamination-limiting dispenser may support institutional or premium retail positioning. Packaging costs and user acceptance determine commercial viability.

Combination or specialty formulation

A nystatin product with a corticosteroid, barrier-support component or advanced delivery system can create a more defensible commercial position. It also increases clinical-development, labeling and patent risk.

Key Takeaways

• Nystatin cream is a mature prescription topical antifungal, usually supplied at 100,000 units/g.
• Conventional products have limited active-ingredient patent protection and face established generic competition.
• Excipients are the principal route to differentiation through tolerability, occlusivity, spreadability, preservative strategy and sensory performance.
• Sensitive-skin, pediatric, long-term-care and telehealth channels offer the clearest commercial opportunities.
• Preservative-free and unit-dose products may create premium positioning but require stronger microbiological and packaging controls.
• Combination products and novel delivery systems can generate stronger IP but carry higher regulatory and clinical risk.
• Generic entry risk is high for an ordinary cream without active formulation or method-of-use patents.
• The strongest commercial formulation claims are those supported by measurable improvements in stability, irritation, delivery, adherence or contamination control.

FAQs

Is nystatin cream available over the counter?

In the United States, standard nystatin cream is generally marketed as a prescription product. OTC status varies by country and dosage form.

Can propylene glycol be removed from nystatin cream?

Yes, but removal can affect solubilization, hydration, viscosity, preservation and skin feel. The revised product requires formulation, stability, microbiological and regulatory assessment.

Is nystatin cream patent protected?

The nystatin active ingredient is mature. Any current protection would more likely involve a specific formulation, delivery system, manufacturing process, packaging configuration or method of use.

Can nystatin cream be made preservative-free?

Yes, potentially through unit-dose or contamination-limiting packaging. The product still requires evidence of microbiological quality throughout its shelf life and use period.

What is the best commercial excipient profile for pediatric nystatin cream?

A fragrance-free, low-irritancy, moderately occlusive cream with a validated preservative or unit-dose packaging strategy is the strongest general development direction. The final profile must match the intended indication and FDA-approved labeling.

References

1. U.S. Food and Drug Administration. (2024). Nystatin cream, USP 100,000 units per gram: Prescribing information. DailyMed.
2. United States Pharmacopeial Convention. (2024). Nystatin monograph and general chapters for semisolid dosage forms. United States Pharmacopeia-National Formulary.
3. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatologic corticosteroids and other topical drug products: Development and regulatory considerations. FDA.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.